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Introduction
Infection with human immunodeficiency virus type 1
(HIV-1) is associated with a variety of well-known
renal diseases like IgA nephropathy, membranous
nephropathy, and haemolytic uraemic syndrome [1].
HIV-associated nephropathy (HIVAN) is now being
recognized as a distinct clinico-pathological entity that
presents with proteinuria in the nephrotic range and
impairment of renal function [1]. Untreated, HIVAN
caries a poor prognosis and invariably leads to end-
stage renal failure within months. The most striking
finding on renal biopsy is collapsing focal glomerulo-
sclerosis, but all renal compartments are essentially
affected [1]. HIVAN is predominantly seen in black
patients and has become a major cause for end-stage
renal disease (ESRD) in this patient group. Treatment
of HIVAN has included the use of steroids, ACE-
inhibition and anti-retroviral drugs but the optimal
treatment is not known [1]. Corticosteroids and ACE-
inhibition probably slow down the progression to
ESRD especially in cases with mild to moderate renal
impairment. An animal model of mice transgenic for
an HIV-1 gene construct suggested a direct pathogenic
effect of HIV on renal cells [2]. Aggressive reduction
of the viral load by a combination of anti-retroviral
drugs, also known as highly active anti-retroviral
therapy (HAART), is now considered standard ther-
apy for HIV-1 infection. Anecdotal data suggest that
marked improvement of renal function may occur
after starting HAART [3]. Preliminary reports showed
a better renal survival for patients with HIVAN
treated with HAART [4,5]. Prospective randomized
clinical trials comparing different treatment regimes
for HIVAN have not been performed. Based on
present data, HAART combined with ACE-inhibition
may be the optimal treatment for HIVAN. In this
report we describe three patients with HIVAN, who
presented with rapidly progressive renal insufficiency
and were not treated previously for their HIV-1
infection. Marked and prolonged improvement of
renal function was established after starting HAART
and ACE-inhibition.
Case 1
A 30-year-old black female patient was admitted with
a 1-week history of general malaise, increase in weight,
and peripheral oedema. Her weight was 72.7 kg and
her blood pressure was 120u60 mmHg. There were
signs of oedema periorbitally and at the lower legs.
Multiple ulcera were present on the buttocks.
Laboratory tests showed a plasma creatinine of
9.17 mgudl, urea 84.0 mgudl, and albumin 17 gul. Two
months before the plasma creatinine concentration
was 0.84 mgudl. The urinary sediment revealed four
to 10 erythrocytes and four to 10 leukocytes per high
power field and urinary protein was 16 guday. Ultra-
sound examination showed normal sized kidneys
measuring 11 cm with increased echogenicity of the
cortex.
HIV-1 antibodies were present and the viral load
was 210 000 copiesuml. The CD4-positive lymphocyte
count was 30umm3. Tests for collagen diseases,
vasculitis, or hepatitis were all negative. Smear cultures
from the skin ulcers were positive for herpes simplex
virus. A renal biopsy was performed. Microscopic
examination revealed 20 glomeruli, all showing a
varying degree of collapse of the capillaries with
areas of proliferation of visceral podocytes. In the
mesangium there was a slight proliferation of
mesangial cells and minimal fibrosis. The tubuli were
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atrophic with cystic dilatation. In the interstitium
some oedema and fibrosis was present with minimal
infiltration of mononuclear cells. A diagnosis of
HIVAN was made but the patient did not accept the
diagnosis of HIV infection and, therefore, refused to
take anti-retroviral medication the first 3 months of
her admission. In these months she was treated with
diuretics and a brief period of ACE-inhibition. Two
months after starting HAART, containing lamivudine,
stavudine, and nevirapin, the viral load had declined
to 1200 copiesuml and the CD4 cell count increased to
280umm3. This was accompanied by a rapid and stable
improvement of renal function (Figure 1, top).
Shortly after admission her clinical course was
further complicated by a Pneumocystis carinii pneu-
monia infection, a pneumonia and bacteraemia caused
by Streptococcus pneumonia and a Candida albicans
esophagitis, for which she was treated successfully.
Eighteenmonths afterpresentation shehadgained20 kg
in weight with stable plasma creatinine concentrations.
Case 2
A 32-year-old male black patient presented with
complaints of general malaise and a short history of
progressive oedema of the lower legs. His blood
pressure was 140u70 mmHg, weight 69 kg, and height
172 cm. There were signs of bilateral pleural effusion
and on the lower legs peripheral oedema extending
to the knees was found. Laboratory investigations
showed a plasma creatinine of 11.3 mgudl, urea
94.4 mgudl, and albumin 16 gul. Two weeks before his
plasma creatinine was 6.8 mgudl. Additional labor-
atory tests revealed a normal urinary sediment on
microscopy with a urinary protein excretion of
13 gu24 h. Tests for collagen diseases, vasculitis, or
hepatitis were negative. Antibodies to HIV-1 were
present. His CD4 lymphocyte count was below the
lower level of detection and the viral load 40 000 viral
copiesuml. Ultrasonography showed large and swollen
kidneys. A percutaneous kidney biopsy could not
be performed because of a prolonged bleeding time
that could not be corrected. He was treated with
furosemide, enalapril, and HAART consisting of
retonavir, saquinavir, lamivudine, and stavudine
(Figure 1). His renal function improved markedly
and the viral load dropped below 50 copiesuml.
Four weeks after starting HAART the bleeding
time was normal and a kidney biopsy was performed.
It showed changes typical for HIVAN. All the 11
glomeruli showed significant segmental or global tuft
collapse with wrinkling of the basal membrane and
epithelial crescents in some of the glomeruli. The
mesangial extracellular matrix was increased with
variable mesangial cell proliferation. The tubuli were
atrophic with cystic dilatation and were embedded
in an interstitium with fibrosis and variable infiltration
of mononuclear cells. On electron-microscopic exam-
ination glomerular endothelial cells showed tubulo-
reticular inclusions. No significant deposits of
immunoglobulins or complement could be detected.
Case 3
A 40-year-old female black patient was seen at the
outpatient clinic of the gastroenterology department
because of weight loss. She used no medication or
drugs. Pneumonia of the middle lobe was diagnosed
which was treated with antibiotics orally. Additional
investigations revealed a positive HIV-1 serology with
a lowered CD4-positive lymphocyte count of 160umm3
and a viral load of 124 000 copiesuml. She was referred
to the outpatient clinic of the department of infectious
diseases. Her blood pressure was 130u85 mmHg and no
signs of oedema were present; plasma creatinine was
0.89 mgudl. Shortly thereafter, she developed a severe
herpes zoster infection ophthalmicus, which was
treated appropriately. Anti-retroviral therapy could
not be started because of problems with the health
insurance. During follow-up, renal function deterior-
ated. The urinary sediment revealed four to 10
erythrocytes and four to 10 leukocytes per high
power field and urinary protein was 17.2 guday.
Serology tests were negative for hepatitis C and
positive for hepatitis B surface and core antibody.
Ultrasonography showed kidneys measuring 11 cm
with a hyperechogenic cortex.
A renal biopsy was performed that contained 34
glomeruli, 13 showing global sclerosis. The other
Fig. 1. Plasma creatinine concentrations (j) and proteinuria (s)
in time (days) of patients described in Case 1 (top), Case 2 (middle),
and Case 3 (bottom). The black bars indicate the period of treatment
with HAART and the dashed bars the period of treatment with
ACE-inhibition.
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glomeruli showed signs of focal glomerulosclerosis
with varying collapse and proliferation of visceral
podocytes. The tubuli were atrophic and dilated. The
interstitium showed infiltration of predominantly
lymphocytes and extensive interstitial fibrosis. Some
granular distribution of IgM and complement was
seen on immunofluorescence examination. Electron
microscopy revealed many tubuloreticular structures
in the endothelial cells of the glomerulus. A diagnosis
of HIVAN was made and patient was treated with
HAART (stavudine, lamivudine, and efavirenz) in
conjunction with ACE-inhibition. The viral load
dropped to 70 copiesuml and the CD4 cell count
increased to 290umm3. The renal function improved
with a decrease in proteinuria (Figure 1).
Discussion
The pathogenesis of HIVAN most probably involves
a direct cytotoxic effect of HIV on renal cells. Hetero-
zygote HIV-1 transgenic mice develop a nephrotic
syndrome that closely resembles the human situation
[2]. Crossover renal transplantation experiments sug-
gested that intrarenal expression of HIV genes is
essential in the pathogenesis [2]. The cytopathic effect
on podocytes leads to dedifferentiation, proliferation,
and loss of contact inhibition thereby causing collaps-
ing glomerulosclerosis and heavy proteinuria [6]. The
mesangial extracellular matrix may be thickened with
increased numbers of mesangial cells. The tubuli are
always affected and show dedifferentiation, atrophy,
and increased apoptosis leading to cystic dilatation.
In the interstitium, extensive fibrosis may be observed
with varying infiltration by mononuclear cells [1].
Electron microscopic examination of the glomerular
endothelial cells frequently reveals tubuloreticular
structures, a feature that is shared with systemic lupus
erythematosus (SLE) nephritis. Their presence could
be caused by the action of interferon-alpha [1].
HIV-1 infects renal cells and the kidney may be an
important long-term reservoir for the virus [5]. The
porte d’entree for HIV-1 is not known as cellular
receptors on renal cells like CD4 or the chemokine
receptors have not been identified beyond doubt [7].
HIVAN usually occurs in patients with an AIDS-
defining diagnosis with high viral loads, suggesting the
importance of a high viral burden in the pathogenesis
of HIVAN [1,8]. Also, the introduction of HAART
has decreased the prevalence of HIVAN. The marked
susceptibility of black HIV-1-infected patients and a
familial disposition for ESRD indicates a strong
genetic predisposition for HIVAN [1].
Based on pathogenic considerations as mentioned
above, the optimal treatment for HIVAN would be
the lowering of viral load. Since the introduction of
HAART, this has now become feasible in most
HIV-1-infected patients in western countries. The
effect of HAART on renal function in patients with
HIVAN is poorly studied, but is probably beneficial
[3–5]. In these reports most patients were already
treated with anti-retroviral drugs or were given steroids
thereby limiting the interpretation of the data.
Monotherapy with a reverse transcriptase inhibitor
like AZT was associated with a better renal prognosis
especially early in the course of the disease [1].
Besides anti-retroviral drugs, corticosteroids and
ACE-inhibition have been employed in the treatment
of HIVAN. Corticosteroids may improve renal func-
tion although data from prospectively randomized
trials are not available [1]. A recently published
retrospective cohort study showed that corticosteroids
are effective in slowing down the progression of renal
dysfunction although most patients became dialysis
dependent after 1 year [1]. The effect of corticosteroids
may be mediated by diminishing the tubulo-interstitial
mononuclear cell infiltrate [9]. Although cortico-
steroids can be safely used for a short-term period
in most HIV patients, they should not be given
to patients with severe opportunistic infections like
Cases 1 and 2.
ACE-inhibition seems particularly beneficial in the
treatment of HIVAN. When given to patients with
modest renal insufficiency and proteinuria, ACE-
inhibition may markedly slow down further progres-
sion of HIVAN [1]. Data from randomized clinical
trials are unfortunately not available but the beneficial
effects of ACE-inhibition were substantiated in
HIV-1 transgenic mice. Captopril given after birth in
these mice largely prevented the clinical and histo-
pathological sequences of HIVAN [10]. The effects of
ACE-inhibition have been attributed to inhibition of
renal fibrosis caused by over expression of transforming
growth factor (TGF)-b and b fibroblast growth factor
(FGF). However, renal TGF-b expression did not differ
between the captopril-treated and control mice [10].
The three patients in this report showed the typical
clinical and pathological characteristics of HIVAN.
They were black, had high viral loads, and impaired
immunity as evidenced by low CD4 lymphocyte counts
and serious infections in Cases 1 and 2. None of them
were using medication or drugs. All three patients
showed a rapid decline in renal function with massive
proteinuria. Renal biopsy revealed the typical collaps-
ing glomerulosclerosis with involvement of all renal
cell compartments and the presence of reticulotubular
structures. Cases 2 and 3 showed rapid improvement
of renal function together with diminishing peripheral
oedema during treatment with furosemide. This
beneficial effect on renal function is probably mediated
partly by diminishing the renal oedema as well, as in
the renal biopsies no other rapidly reversible factor
could be identified. Further improvement occurred
with effective lowering of the viral load by giving
HAART. The additional role of ACE-inhibition is
unclear, although in Case 1 the proteinuria decreased
markedly on furosemide and ACE-inhibition without
HAART. This patient stopped the use of ACE-
inhibition early in the course of treatment but never-
theless showed an excellent and stable improvement of
renal function after starting HAART. Corticosteroids
were not given because of the co-existence of severe
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infections and the good response on HAART and
ACE-inhibition. In all the patients HAART was con-
tinued but the effect on long-range renal function
remains to be established.
The rapid progression of renal dysfunction in
HIVAN combines usually with an impressive amount
of irreversible renal damage. The ultimate recovery
of renal function is dependent on the amount of
glomerulosclerosis and interstitial fibrosis. The col-
lapsed glomerulus with little or no sclerosis may
recover completely [3]. In our cases no follow-up
biopsies were performed.
Based on our preliminary data it appears that
HAART with ACE-inhibition should be the treatment
of choice in HIVAN and that stable and impressive
improvement in renal function can be achieved. It
should be noted that the clearance of several anti-
retroviral drugs is dependent on renal function and,
therefore, dosage reductions or interval extensions
should be made according to the existing guidelines.
The use of corticosteroids can be reserved for patients
that do not respond favourably to this therapy and
have a dense tubulo-interstitial cell infiltrate. Early
recognition and treatment is of paramount importance
to minimize irreversible renal damage and optimally
preserve renal function. The importance is further
stressed by the fact that HIVAN is now the third
leading cause of ESRD in blacks in the USA [1].
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